Pfizer Survey Reveals 67% of Older Adults Prioritize Respiratory Infection Prevention
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 day ago0mins
- Increased Health Awareness: Pfizer's survey indicates that 67% of older adults prioritize protecting their health to avoid respiratory infections, reflecting a significant rise in health consciousness that could drive demand for related health products.
- Active Lifestyle Impact: With 60% of respondents engaging in leisure activities multiple times a week, this active lifestyle not only supports individual health but may also alleviate pressure on healthcare systems and enhance community vitality.
- Sense of Family Responsibility: The survey reveals that 49% of respondents feel a responsibility to stay healthy to care for others, suggesting that this sense of duty may encourage more older adults to adopt preventive measures, thereby influencing the market demand for vaccinations and health products.
- Awareness of Preventive Measures: Over 75% of respondents recognize the importance of vaccinations and handwashing, indicating that Pfizer's efforts to raise public health awareness could enhance its brand image and boost sales of related products.
PFE.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
10 Hold
1 Sell
Hold
Current: 25.800
Low
24.00
Averages
29.08
High
34.00
Current: 25.800
Low
24.00
Averages
29.08
High
34.00
HSBC
Rajesh Kumar
Buy
maintain
$28 -> $29
2025-12-10
New
Reason
HSBC
Rajesh Kumar
Price Target
$28 -> $29
2025-12-10
New
maintain
Buy
Reason
HSBC analyst Rajesh Kumar raised the firm's price target on Pfizer to $29 from $28 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
Guggenheim
Buy
maintain
$33 -> $35
2025-11-24
Reason
Guggenheim
Price Target
$33 -> $35
2025-11-24
maintain
Buy
Reason
Guggenheim raised the firm's price target on Pfizer to $35 from $33 and keeps a Buy rating on the shares. Pfizer's acquisition of Metsera is "a wise strategic move" to gain traction in the rapidly growing obesity market following recent setbacks with the company's internal oral GLP-1 programs, the analyst tells investors.
Scotiabank
Outperform
initiated
$30
2025-11-12
Reason
Scotiabank
Price Target
$30
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Pfizer with an Outperform rating and $30 price target.
BofA
Tim Anderson
Neutral
maintain
$28
2025-10-01
Reason
BofA
Tim Anderson
Price Target
$28
2025-10-01
maintain
Neutral
Reason
The timing of the "deal" announced between the U.S. and Pfizer on drug pricing "may have come as a surprise," but the substance of it didn't, in the opinion of BofA analyst Tim Anderson, whose view over the last weeks-to-months has been that the drug industry might well escape any real pain when negotiating on issues like "most favored nation" drug pricing. Press releases from the White House and from Pfizer "largely lack specifics, but both read as benign," adds the analyst, who calls the agreement "a loose collection of measures that likely doesn't cost Pfizer much, yet still provides the Administration with a political win." The firm keeps a Neutral rating and $28 price target on Pfizer shares.
See All Ratings
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key features of Pfizer's HYMPAVZI for hemophilia treatment?
How does Pfizer's licensing deal with YaoPharma enhance its obesity pipeline?
Will Pfizer's obesity drug market entry significantly impact its revenue by 2030?
How likely is HYMPAVZI to gain FDA and EMA approval soon?